Clinical trial
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
NCT00348595 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00348595 |
|---|---|
| Title | Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer |
| Official title | Phase I/II Double Blinded Randomized Study to Determine the Tolerability and Efficacy of 2 Different Doses of Revlimid (CC-5013, Lenalidomide) in Biochemically Relapsed Prostate Cancer Patients (M0) After Local Treatment |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Revlimid |
| Enrollment | 77 |
| Start date | Jul 20, 2006 |
| Primary completion | Jun 29, 2016 |
| Completion | Jun 29, 2016 |
| First posted | Jul 4, 2006 |
| Last update posted | Apr 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: